Latest Bristol-Myers Squibb Stories
RARITAN, N.J., Jan. 16, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today the U.S.
QINGDAO, China and ROCKVILLE, Md., Jan. 14, 2014 /PRNewswire/ -- Synutra International, Inc.
The FDA has approved the use of a new type 2 diabetes drug called Farxiga, developed by pharmaceutical companies Bristol-Meyers Squibb and AstraZeneca.
Pharma Industry Veteran Brings Full-Spectrum Healthcare Expertise to One of Venture Industry's Most Active Life Sciences Investors CHEVY CHASE, Md. and MENLO PARK, Calif., Jan.
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, January 9, 2014 /PRNewswire/ -- Today, Analysts' Corner announced new research
- First approved combination of oral targeted therapies for unresectable or metastatic melanoma with BRAF V600E or V600K mutations LONDON, Jan.
The epidermal growth factor receptor (EGFR) is expressed in normal colonic cells and is activated by specific peptide growth factors that regulate cell proliferation, survival and differentiation.